suramin has been researched along with Adenocarcinoma in 43 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 7.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "Suramin, a polysulphonated naphthylurea proven to be an effective anticancer agent against selected tumours, and alpha 2A-interferon (alpha 2A-IFN) were investigated for their combined effects on HCT-8, HCT-15, CL-D, SW-480 and SW-620 human colorectal adenocarcinoma cell lines." | 7.69 | Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. ( Andreuccetti, M; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Malvaldi, G; Pfanner, E; Pieracci, D; Zaccaro, L, 1994) |
| "In this report we demonstrated that [3H]suramin enters polarized human colon adenocarcinoma cells when added to the apical side of the monolayer." | 7.68 | Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1993) |
| "Suramin, a drug that binds to several types of growth factors, has been previously shown to induce the enterocyte-like differentiation of HT29-D4 human colonic adenocarcinoma cells, suggesting that growth factors are involved in such a process." | 7.68 | Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line. ( el Atiq, F; Garrouste, FL; Marvaldi, JL; Pommier, GJ; Remacle-Bonnet, MM; Roccabianca, M, 1992) |
| "Suramin, a drug currently used for advanced malignancy, induces the differentiation of the human colonic adenocarcinoma cell clone HT29-D4 and this process is correlated with a decreased glycolytic activity." | 7.68 | The concentration of glucose in the culture medium determines the effect of suramin on the growth and differentiation of the human colonic adenocarcinoma cell clone HT29-D4. ( Baghdiguian, S; Brunet, M; Fantini, J; Marvaldi, J; Rabenandrasana, C; Roccabianca, M, 1990) |
| "Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis." | 6.69 | A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. ( Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000) |
| "Emodin is an anthraquinone derivative originally isolated from Chinese rhubarb, possesses anticancer properties." | 5.46 | Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells. ( Guan, R; Li, L; Shen, L; Song, N; Wang, X; Zhu, D, 2017) |
| "Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury." | 5.43 | Suramin protects from cisplatin-induced acute kidney injury. ( Arteel, GE; Beverly, LJ; Casson, L; Doll, MA; Dupre, TV; Jenson, AB; Kiefer, A; Megyesi, J; Saforo, D; Saurabh, K; Scherzer, MT; Schnellmann, RG; Shah, PP; Sharp, CN; Siow, D; Siskind, LJ, 2016) |
| "Furthermore, suramin also inhibited bone resorption in organ cultures of fetal rat long bones and resorption pit formation by isolated mature rat osteoclasts." | 5.29 | Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. ( Boyce, BF; Dunstan, C; Mundy, GR; Rhine, C; Williams, P; Yoneda, T, 1995) |
| "At present there is no effective treatment for cachexia." | 5.29 | Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. ( D'Alessandro, F; Fong, M; Freter, CE; Nordan, RP; Strassmann, G; Windsor, S, 1993) |
| "Suramin is a polysulphonated naphthylurea currently investigated for the treatment of advanced malignancy." | 5.29 | Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1996) |
| "Patients with histologically confirmed advanced hormone-refractory adenocarcinoma of the prostate were randomized to receive suramin at a low dose (n = 129; median age, 69 years), an intermediate dose (n = 129; median age, 71 years), or a high dose (n = 127; median age, 70 years) as part of the Intergroup 0159/Cancer and Leukemia Group B 9480 trial." | 5.11 | Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. ( Ahles, TA; Herndon, JE; Holland, JC; Kornblith, AB; Marshall, ME; Palchak, D; Petrylak, D; Ratain, MJ; Small, EJ; Stadler, W; Vogelzang, NJ; Wilding, G, 2004) |
| " As a result, mitoxantrone plus prednisone has been demonstrated to be a useful palliative therapy that provides improvements in pain and quality of life for approximately 40% of those treated." | 4.81 | Treatment of hormone refractory prostate cancer. ( Knox, JJ; Moore, MJ, 2001) |
| "Recent study found that suramin could inhibit the growth of malignant tumors, but its in vivo effect on lung adenocarcinoma has seldom been reported." | 3.74 | [Inhibitory effects of suramin on growth of transplanted lung adencarcinoma in mice and its mechanisms]. ( He, JB; Xiang, Z; Xie, MF; Yang, K; Yi, GZ; Zhang, P, 2008) |
| " This study was to explore the inhibitory effect of angiogenesis inhibitor Suramin in combination with cisplatin (DDP) on the growth and lung metastasis of lung adenocarcinoma LA795 cell xenografts in mice." | 3.73 | [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice]. ( He, JB; Ou, LW; Wang, XH; Zhang, P, 2006) |
| "Suramin, a polysulphonated naphthylurea proven to be an effective anticancer agent against selected tumours, and alpha 2A-interferon (alpha 2A-IFN) were investigated for their combined effects on HCT-8, HCT-15, CL-D, SW-480 and SW-620 human colorectal adenocarcinoma cell lines." | 3.69 | Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies. ( Andreuccetti, M; Cianci, C; Conte, PF; Danesi, R; Del Tacca, M; Falcone, A; Malvaldi, G; Pfanner, E; Pieracci, D; Zaccaro, L, 1994) |
| "In this report we demonstrated that [3H]suramin enters polarized human colon adenocarcinoma cells when added to the apical side of the monolayer." | 3.68 | Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1993) |
| "Suramin, a drug that binds to several types of growth factors, has been previously shown to induce the enterocyte-like differentiation of HT29-D4 human colonic adenocarcinoma cells, suggesting that growth factors are involved in such a process." | 3.68 | Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line. ( el Atiq, F; Garrouste, FL; Marvaldi, JL; Pommier, GJ; Remacle-Bonnet, MM; Roccabianca, M, 1992) |
| "Suramin, a drug currently used for advanced malignancy, induces the differentiation of the human colonic adenocarcinoma cell clone HT29-D4 and this process is correlated with a decreased glycolytic activity." | 3.68 | The concentration of glucose in the culture medium determines the effect of suramin on the growth and differentiation of the human colonic adenocarcinoma cell clone HT29-D4. ( Baghdiguian, S; Brunet, M; Fantini, J; Marvaldi, J; Rabenandrasana, C; Roccabianca, M, 1990) |
| "Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis." | 2.69 | A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients. ( Benson, AB; Bouck, N; Cisneros, A; French, S; Gradishar, WJ; Liu, J; Rademaker, A; Soff, G, 2000) |
| "Using this dosing schedule, suramin has limited activity against hormone-refractory metastatic prostate cancer." | 2.68 | Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. ( Belldegrun, A; deKernion, J; Graves, MC; Landaw, EM; McBride, JH; Mendoza, EF; Mondino, B; Rosen, PJ; Turcillo, P, 1996) |
| "Ten patients with hormone-refractory prostate cancer received a fixed dosing scheme of suramin infusion in combination with weekly epidoxorubicin at 25 mg/m2." | 2.68 | Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study. ( Boccardo, F; Canobbio, L; Esposito, M; Granetto, C; Miglietta, L; Vannozzi, MO, 1997) |
| "Metastatic prostate cancer is a leading cause of cancer-related death in men." | 2.40 | Treatment options in androgen-independent prostate cancer. ( Lara, PN; Meyers, FJ, 1999) |
| "Emodin is an anthraquinone derivative originally isolated from Chinese rhubarb, possesses anticancer properties." | 1.46 | Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells. ( Guan, R; Li, L; Shen, L; Song, N; Wang, X; Zhu, D, 2017) |
| "Suramin treatment before cisplatin administration reduced cisplatin-induced decreases in kidney function and injury." | 1.43 | Suramin protects from cisplatin-induced acute kidney injury. ( Arteel, GE; Beverly, LJ; Casson, L; Doll, MA; Dupre, TV; Jenson, AB; Kiefer, A; Megyesi, J; Saforo, D; Saurabh, K; Scherzer, MT; Schnellmann, RG; Shah, PP; Sharp, CN; Siow, D; Siskind, LJ, 2016) |
| "Suramin inhibited the proliferation of pancreatic cancer cells in a dose-dependent manner and reduced viability at high concentrations." | 1.34 | Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer. ( Bhargava, S; Buhr, HJ; Hines, OJ; Hotz, B; Hotz, HG; Reber, HA, 2007) |
| "We describe a patient with metastatic prostate cancer who developed nonoliguric renal failure during treatment with suramin." | 1.30 | Acute renal failure in a patient receiving treatment with suramin. ( Harbour, D; Liebmann, J; Smith, A, 1997) |
| "(c) Suramin-treated rats had markedly decreased lymphocyte stimulation, pointing to a possible immunosuppressive effect." | 1.30 | Effects of suramin on anastomotic colon tumors in a rat model. ( De Clerck, LS; Dirix, L; Eyskens, E; Hendriks, J; Hubens, A; Hubens, G; Lauwers, P; Schuerwegh, A; Stevens, WJ; Van Marck, E; Vermeulen, P, 1999) |
| "Furthermore, suramin also inhibited bone resorption in organ cultures of fetal rat long bones and resorption pit formation by isolated mature rat osteoclasts." | 1.29 | Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer. ( Boyce, BF; Dunstan, C; Mundy, GR; Rhine, C; Williams, P; Yoneda, T, 1995) |
| "At present there is no effective treatment for cachexia." | 1.29 | Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo. ( D'Alessandro, F; Fong, M; Freter, CE; Nordan, RP; Strassmann, G; Windsor, S, 1993) |
| "Suramin is a polysulphonated naphthylurea currently investigated for the treatment of advanced malignancy." | 1.29 | Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography. ( Baghdiguian, S; Boudier, JA; Boudier, JL; Fantini, J, 1996) |
| "Suramin is an anti-helminthic drug that has been shown to antagonize the effects of a variety of growth factors including EGF, PDGF and TGF beta." | 1.28 | [Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6]. ( Baghdiguian, S; Fantini, J; Marvaldi, J; Pichon, J, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.65) | 18.7374 |
| 1990's | 28 (65.12) | 18.2507 |
| 2000's | 10 (23.26) | 29.6817 |
| 2010's | 3 (6.98) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, X | 1 |
| Li, L | 1 |
| Guan, R | 1 |
| Zhu, D | 1 |
| Song, N | 1 |
| Shen, L | 1 |
| Dupre, TV | 1 |
| Doll, MA | 1 |
| Shah, PP | 1 |
| Sharp, CN | 1 |
| Kiefer, A | 1 |
| Scherzer, MT | 1 |
| Saurabh, K | 1 |
| Saforo, D | 1 |
| Siow, D | 1 |
| Casson, L | 1 |
| Arteel, GE | 1 |
| Jenson, AB | 1 |
| Megyesi, J | 1 |
| Schnellmann, RG | 1 |
| Beverly, LJ | 1 |
| Siskind, LJ | 1 |
| Atkinson, TM | 1 |
| Halabi, S | 2 |
| Bennett, AV | 1 |
| Rogak, L | 1 |
| Sit, L | 1 |
| Li, Y | 1 |
| Kaplan, E | 1 |
| Basch, E | 1 |
| Ahles, TA | 1 |
| Herndon, JE | 1 |
| Small, EJ | 3 |
| Vogelzang, NJ | 1 |
| Kornblith, AB | 1 |
| Ratain, MJ | 1 |
| Stadler, W | 1 |
| Palchak, D | 1 |
| Marshall, ME | 1 |
| Wilding, G | 1 |
| Petrylak, D | 1 |
| Holland, JC | 1 |
| Zhang, P | 2 |
| He, JB | 2 |
| Ou, LW | 1 |
| Wang, XH | 1 |
| Bhargava, S | 1 |
| Hotz, B | 1 |
| Hines, OJ | 1 |
| Reber, HA | 1 |
| Buhr, HJ | 1 |
| Hotz, HG | 1 |
| Yi, GZ | 1 |
| Yang, K | 1 |
| Xiang, Z | 1 |
| Xie, MF | 1 |
| Tatoud, R | 1 |
| Desgrandchamps, F | 1 |
| DeGeorges, A | 1 |
| Thomas, F | 1 |
| Garrido, T | 1 |
| Riese, HH | 1 |
| Aracil, M | 1 |
| Pérez-Aranda, A | 1 |
| Yoneda, T | 1 |
| Williams, P | 1 |
| Rhine, C | 1 |
| Boyce, BF | 1 |
| Dunstan, C | 1 |
| Mundy, GR | 1 |
| Favoni, RE | 1 |
| Ravera, F | 1 |
| Pirani, P | 1 |
| Ardizzoni, A | 1 |
| Noonan, D | 1 |
| de Cupis, A | 1 |
| Falcone, A | 1 |
| Danesi, R | 2 |
| Zaccaro, L | 1 |
| Pieracci, D | 1 |
| Pfanner, E | 1 |
| Cianci, C | 1 |
| Andreuccetti, M | 1 |
| Malvaldi, G | 1 |
| Del Tacca, M | 1 |
| Conte, PF | 1 |
| Rosell, D | 1 |
| Robles, JE | 1 |
| Aguera, L | 1 |
| Abad, JI | 1 |
| Rodríguez-Rubio, FI | 1 |
| Zudaire, JJ | 1 |
| Berian, JM | 1 |
| Strassmann, G | 1 |
| Fong, M | 1 |
| Freter, CE | 1 |
| Windsor, S | 1 |
| D'Alessandro, F | 1 |
| Nordan, RP | 1 |
| Baghdiguian, S | 5 |
| Boudier, JA | 3 |
| Boudier, JL | 2 |
| Fantini, J | 8 |
| Rosen, PJ | 1 |
| Mendoza, EF | 1 |
| Landaw, EM | 1 |
| Mondino, B | 1 |
| Graves, MC | 1 |
| McBride, JH | 1 |
| Turcillo, P | 1 |
| deKernion, J | 1 |
| Belldegrun, A | 1 |
| Lokshin, A | 1 |
| Levitt, ML | 1 |
| Smith, A | 1 |
| Harbour, D | 1 |
| Liebmann, J | 1 |
| Miglietta, L | 1 |
| Canobbio, L | 1 |
| Granetto, C | 1 |
| Vannozzi, MO | 1 |
| Esposito, M | 1 |
| Boccardo, F | 1 |
| Kenner, JR | 1 |
| Sperling, LC | 1 |
| Waselenko, J | 1 |
| Dawson, N | 1 |
| Sau, P | 1 |
| Moul, JW | 1 |
| Moore-Hoon, ML | 1 |
| Turner, RJ | 1 |
| Lara, PN | 1 |
| Meyers, FJ | 1 |
| Lauwers, P | 1 |
| Hubens, G | 1 |
| Hendriks, J | 1 |
| Vermeulen, P | 1 |
| Schuerwegh, A | 1 |
| Stevens, WJ | 1 |
| De Clerck, LS | 1 |
| Dirix, L | 1 |
| Van Marck, E | 1 |
| Hubens, A | 1 |
| Eyskens, E | 1 |
| Gradishar, WJ | 1 |
| Soff, G | 1 |
| Liu, J | 1 |
| Cisneros, A | 1 |
| French, S | 1 |
| Rademaker, A | 1 |
| Benson, AB | 1 |
| Bouck, N | 1 |
| Song, S | 1 |
| Wientjes, MG | 1 |
| Gan, Y | 1 |
| Au, JL | 1 |
| McMillan, A | 1 |
| Meyer, M | 1 |
| Chen, L | 1 |
| Slichenmyer, WJ | 1 |
| Lenehan, PF | 1 |
| Eisenberger, M | 1 |
| Kantoff, PW | 1 |
| Farmer, DA | 1 |
| Hayes, DF | 1 |
| Vogelzang, NA | 1 |
| Knox, JJ | 1 |
| Moore, MJ | 1 |
| Heicappell, R | 1 |
| Pommier, GJ | 1 |
| Garrouste, FL | 1 |
| el Atiq, F | 1 |
| Roccabianca, M | 3 |
| Marvaldi, JL | 1 |
| Remacle-Bonnet, MM | 1 |
| Weckbecker, G | 1 |
| Liu, R | 1 |
| Tolcsvai, L | 1 |
| Leith, JT | 1 |
| Papa, G | 1 |
| Quaranto, L | 1 |
| Michelson, S | 1 |
| Verrier, B | 2 |
| Zappitelli, JP | 1 |
| Scher, HI | 1 |
| Jodrell, DI | 1 |
| Iversen, JM | 1 |
| Curley, T | 1 |
| Tong, W | 1 |
| Egorin, MJ | 1 |
| Forrest, A | 1 |
| Pichon, J | 2 |
| Marvaldi, J | 5 |
| La Rocca, RV | 1 |
| Cooper, MR | 1 |
| Jamis-Dow, CA | 1 |
| Ewing, MW | 1 |
| Linehan, WM | 1 |
| Myers, CE | 2 |
| Wellstein, A | 1 |
| Lupu, R | 1 |
| Zugmaier, G | 1 |
| Flamm, SL | 1 |
| Cheville, AL | 1 |
| Delli Bovi, P | 1 |
| Basilico, C | 1 |
| Lippman, ME | 1 |
| Kern, FG | 1 |
| Robert, C | 1 |
| Pic, P | 1 |
| Mauchamp, J | 1 |
| Rognoni, JB | 2 |
| Theveniau, M | 1 |
| Pommier, G | 2 |
| Rabenandrasana, C | 1 |
| Brunet, M | 1 |
| Stein, CA | 1 |
| LaRocca, RV | 1 |
| Thomas, R | 1 |
| McAtee, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE III STUDY OF THREE DIFFERENT DOSES OF SURAMIN (NSC #34936) ADMINISTERED WITH A FIXED DOSING SCHEDULE IN PATIENTS WITH ADVANCED PROSTATE CANCER[NCT00002723] | Phase 3 | 390 participants (Actual) | Interventional | 1996-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for suramin and Adenocarcinoma
| Article | Year |
|---|---|
[Peptide growth factors in the prostate].
Topics: Adenocarcinoma; Epidermal Growth Factor; Fibroblast Growth Factors; Humans; Interleukin-6; Male; Ner | 1993 |
Treatment options in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antibodies, Monoclonal; Antineoplastic Agents; Anti | 1999 |
Treatment of hormone refractory prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Est | 2001 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Ag | 2002 |
7 trials available for suramin and Adenocarcinoma
| Article | Year |
|---|---|
Measurement of affective and activity pain interference using the Brief Pain Inventory (BPI): Cancer and Leukemia Group B 70903.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Factor Analysis, Statistical; | 2012 |
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormon | 2004 |
Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Half-Life; Humans; Male; Middle Aged; Neop | 1996 |
Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Humans; Male; Pilot Proj | 1997 |
A pilot trial of suramin in metastatic breast cancer to assess antiangiogenic activity in individual patients.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Female | 2000 |
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Biomarkers, Tumor; Dis | 2001 |
Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; M | 2001 |
32 other studies available for suramin and Adenocarcinoma
| Article | Year |
|---|---|
Emodin Inhibits ATP-Induced Proliferation and Migration by Suppressing P2Y Receptors in Human Lung Adenocarcinoma Cells.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Adenosine Triphosphate; bcl-2-Associated X Prote | 2017 |
Suramin protects from cisplatin-induced acute kidney injury.
Topics: Acute Kidney Injury; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; C | 2016 |
[Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Synergi | 2006 |
Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor | 2007 |
[Inhibitory effects of suramin on growth of transplanted lung adencarcinoma in mice and its mechanisms].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Immunohistochemist | 2008 |
Endothelial cell differentiation into capillary-like structures in response to tumour cell conditioned medium: a modified chemotaxis chamber assay.
Topics: Adenocarcinoma; Animals; Antibodies; Aorta; Breast Neoplasms; Capillaries; Cattle; Cell Differentiat | 1995 |
Suramin suppresses hypercalcemia and osteoclastic bone resorption in nude mice bearing a human squamous cancer.
Topics: Adenocarcinoma; Animals; Bone and Bones; Bone Resorption; Calcium; Carcinoma, Squamous Cell; Cell Di | 1995 |
Suramin interferes with auto/paracrine insulin-like growth factor I-controlled proliferative loop on human lung cancer cell lines.
Topics: Adenocarcinoma; Binding, Competitive; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell | 1994 |
Synergistic antiproliferative activity of suramin and alpha 2A-interferon against human colorectal adenocarcinoma cell lines: in vitro studies.
Topics: Adenocarcinoma; Cell Division; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug | 1994 |
[Potentiation of cytotoxicity of electromagnetic shock waves by suramin, "in vitro" study].
Topics: Adenocarcinoma; Cell Division; Combined Modality Therapy; Dose-Response Relationship, Radiation; Hum | 1994 |
Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.
Topics: Adenocarcinoma; Animals; Cachexia; Colonic Neoplasms; Humans; Interleukin-6; Liver; Male; Mice; Mice | 1993 |
Autoradiographic localization of tritiated suramin in polarized human colon adenocarcinoma cells.
Topics: Adenocarcinoma; Autoradiography; Biological Transport; Cell Nucleus; Colonic Neoplasms; Cytoplasm; H | 1993 |
Effect of suramin on squamous differentiation and apoptosis in three human non-small-cell lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcimycin; Carcinoma, Adenosquamous; Carcinoma, S | 1996 |
Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: a study by quantitative autoradiography.
Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Colonic Neoplasms; Humans; Microscopy, Elect | 1996 |
Acute renal failure in a patient receiving treatment with suramin.
Topics: Acute Kidney Injury; Adenocarcinoma; Androgen Antagonists; Anti-Inflammatory Agents; Antineoplastic | 1997 |
Suramin keratosis: a unique skin eruption in a patient receiving suramin for metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Eruptions; Humans; Keratosis; Male; Prostatic Neop | 1997 |
Increased expression of the secretory Na+-K+-2Cl- cotransporter with differentiation of a human intestinal cell line.
Topics: Adenocarcinoma; Blotting, Northern; Blotting, Western; Butyrates; Butyric Acid; Carrier Proteins; Ce | 1998 |
Effects of suramin on anastomotic colon tumors in a rat model.
Topics: Adenocarcinoma; Anastomosis, Surgical; Animals; Antineoplastic Agents; Cell Survival; Colon; Colonic | 1999 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic | 2000 |
Potential autocrine role of insulin-like growth factor II during suramin-induced differentiation of HT29-D4 human colonic adenocarcinoma cell line.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Carrier Proteins; Cell Differentiation; Cell Line; Colonic | 1992 |
Intradermal angiogenesis in nude mice induced by human tumor cells or b-FGF.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line; Female; Fibroblast G | 1992 |
Modification of the volumetric growth responses and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dose-Response R | 1992 |
[Suramin induces lysosomal storage disorder in HT29-D4 cells during a mechanism of polarized endocytosis].
Topics: Adenocarcinoma; Cell Line, Transformed; Cell Transformation, Neoplastic; Clone Cells; Colonic Neopla | 1992 |
Use of adaptive control with feedback to individualize suramin dosing.
Topics: Adenocarcinoma; Aged; Algorithms; Humans; Male; Middle Aged; Prostatic Neoplasms; Suramin; Time Fact | 1992 |
[Suramin inhibits the proliferation and stimulates the differentiation of tumoral cell lines HT29-D4 and C6].
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Transformed; Cell Transformation, Neoplastic; Col | 1991 |
Effect of suramin on human prostate cancer cells in vitro.
Topics: Adenocarcinoma; Androstenedione; Antineoplastic Agents; Cell Line; Dehydroepiandrosterone; Dehydroep | 1991 |
Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor.
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Animals; Down-Regulation; Fibroblast Growth Factor 2; Fibr | 1990 |
Suramin-induced differentiation of the human colic adenocarcinoma cell clone HT29-D4 in serum-free medium.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Cell Count; Cell Differentiation; Cell Division; Clone Cel | 1990 |
Impaired carcinoembryonic antigen release during the process of suramin-induced differentiation of the human colonic adenocarcinoma cell clone HT29-D4.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Cell Membrane; Cell Transformation, Neoplastic; Colonic Ne | 1990 |
The concentration of glucose in the culture medium determines the effect of suramin on the growth and differentiation of the human colonic adenocarcinoma cell clone HT29-D4.
Topics: Adenocarcinoma; Colonic Neoplasms; Culture Media; Glucose; Humans; In Vitro Techniques; Microscopy, | 1990 |
Suramin inhibits cell growth and glycolytic activity and triggers differentiation of human colic adenocarcinoma cell clone HT29-D4.
Topics: Adenocarcinoma; Alkaline Phosphatase; Cell Differentiation; Cell Division; Cell Line; Colonic Neopla | 1989 |
Suramin: an anticancer drug with a unique mechanism of action.
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Adult; Antineoplastic Agents; Carcinoma; Female; Humans; K | 1989 |